Takeda Pharmaceutical (TKPHF) EBT (2017 - 2026)

Takeda Pharmaceutical's EBT history runs 10 years deep, the most recent figure standing at -$334.6 million for Q1 2026.

• In Q1 2026, EBT fell 114.48% year-over-year to -$334.6 million; the TTM figure through Mar 2026 stood at $8.9 billion (down 13.18% YoY), while the FY2026 annual figure was $1.7 billion, up 50.38% from the prior year.
• EBT was -$334.6 million for Q1 2026 at Takeda Pharmaceutical, down from $1.1 billion in the prior quarter.
• In the past five years, EBT ranged from a high of $6.1 billion in Q3 2025 to a low of -$334.6 million in Q1 2026.
• Historically, EBT has averaged $1.7 billion across 5 years, with a median of $1.2 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: EBT sank 127.28% in 2024, then jumped 820.73% in 2025.
• A 5-year view of EBT shows it stood at $758.5 million in 2022, then surged by 87.22% to $1.4 billion in 2023, then decreased by 27.65% to $1.0 billion in 2024, then grew by 5.17% to $1.1 billion in 2025, then sank by 130.97% to -$334.6 million in 2026.
• The last three EBT figures came in at -$334.6 million (Q1 2026), $1.1 billion (Q4 2025), and $6.1 billion (Q3 2025), per Business Quant data.